Cost-effectiveness Of Cancer With Screening Test And No

As the improvement of people’s lives in21st century, the incidence rate of all kinds of diseases goes up in an increasingly way, especially the cancer which has become the biggest threat to our lives. In2008, according to the GLOBOCAN issued by the International Agency for Research on Cancer, there are7.6million people died of the Cancer which covers the13%of total death. By2030, there will be more than11million people died of cancer. Therefore, it is imperative for all the countries to increase investment in cancer treatment. In the medical field, the developed countries make an extensive use of Markov model to do an empirical analysis, which provide the theoretical basis to improve the financial expenditure on the Medical. While this kind of research in China is few. Hence, this article is to provide some suggestions to the government by introducing the Markov-model into the medical area and comparing the cost-benefit analysis results between the screening test and no-screening test.There are four parts in this paper. In part1, we have a brief introduction of research background, innovations and methods used in this paper, and also basic situation of the cancers in the world which indicates the importance of the improvements and efforts should be taken in the area of the medical. To understand the complicated process of the people who are involving the disease in an easy approach, the Markov Model is used to simulate the situation in the reality. The cancer is divided into three stages:Low-risk stage, medium risk and high-risk. Hence, the basic theory of the Markov Model and the difference between no-screening test and screening test are introduced in the part2. We study the three different stages of the cancers which are low-risk stage, medium-risk stage and high-risk stage. In part3, based on the reality, the parameters are assumed to run the simulations. We take the ten time-periods and3%discounted rate to calculate the total effectiveness and cost, and compare the no-screening test with screening test by the cost-benefit analysis. In the last part, on the base of the result of the ICER and analysis on the screening test, some suggestions are provided to improve the financial expenditure and difficult position of the cancers.